JPMorgan Chase & Co. restated their sell rating on shares of Jounce Therapeutics (NASDAQ:JNCE) in a research note published on Sunday, AnalystRatings.com reports.

JNCE stock opened at $4.25 on Friday. The company has a quick ratio of 2.03, a current ratio of 2.03 and a debt-to-equity ratio of 0.20. Jounce Therapeutics has a 52-week low of $2.66 and a 52-week high of $8.58. The business’s 50 day simple moving average is $4.45. The stock has a market cap of $138.52 million, a P/E ratio of -5.06 and a beta of 3.44.

Jounce Therapeutics (NASDAQ:JNCE) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.05. Jounce Therapeutics had a negative return on equity of 29.64% and a negative net margin of 46.07%. The company had revenue of $17.45 million for the quarter, compared to the consensus estimate of $17.09 million. Equities research analysts anticipate that Jounce Therapeutics will post 0.72 EPS for the current fiscal year.

Hedge funds have recently bought and sold shares of the business. Meeder Asset Management Inc. increased its holdings in Jounce Therapeutics by 249.6% during the 2nd quarter. Meeder Asset Management Inc. now owns 5,034 shares of the company’s stock worth $25,000 after purchasing an additional 3,594 shares during the last quarter. Algert Global LLC bought a new stake in shares of Jounce Therapeutics in the 1st quarter valued at approximately $88,000. Bailard Inc. bought a new stake in shares of Jounce Therapeutics in the 1st quarter valued at approximately $92,000. Raymond James & Associates bought a new stake in shares of Jounce Therapeutics in the 4th quarter valued at approximately $71,000. Finally, Bank of America Corp DE increased its holdings in shares of Jounce Therapeutics by 37.4% in the 4th quarter. Bank of America Corp DE now owns 35,082 shares of the company’s stock valued at $118,000 after acquiring an additional 9,544 shares during the last quarter. Institutional investors own 73.54% of the company’s stock.

About Jounce Therapeutics

Jounce Therapeutics, Inc, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase I/II clinical trial for the treatment of head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, gastric cancer, and other tumor types identified through its translational science platform.

Featured Story: How to start trading in the forex market?

Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.